U.S. Markets close in 1 hr 50 mins
  • S&P 500

    4,567.25
    +22.35 (+0.49%)
     
  • Dow 30

    35,748.16
    +71.14 (+0.20%)
     
  • Nasdaq

    15,226.19
    +135.99 (+0.90%)
     
  • Russell 2000

    2,311.30
    +20.03 (+0.87%)
     
  • Gold

    1,808.20
    +11.90 (+0.66%)
     
  • EUR/USD

    1.1617
    -0.0028 (-0.2440%)
     
  • 10-Yr Bond

    1.6340
    -0.0210 (-1.27%)
     
  • Vix

    15.22
    -0.21 (-1.36%)
     
  • GBP/USD

    1.3773
    +0.0014 (+0.1005%)
     
  • USD/JPY

    113.6610
    +0.2010 (+0.1772%)
     
  • BTC-USD

    62,987.04
    +2,818.05 (+4.68%)
     
  • CMC Crypto 200

    1,505.60
    +1,262.92 (+520.41%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Inovio To Start Global Late-Stage COVID-19 Vaccine Trial

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc's (NASDAQ: INO) global Phase 3 segment of its INNOVATE Phase 2/3 trial for INO-4800, DNA COVID-19 vaccine candidate.

  • Related Content: Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study.

  • Inovio plans to conduct the global Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co Ltd.

  • Phase 3 will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart.

  • The primary endpoint of the trial is virologically confirmed COVID-19.

  • Also Read: Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants.

  • Earlier this month, China signed off two clinical trials for heterologous boosting with INO-4800 through Advaccine as the trial sponsor.

  • Working with Sinovac Biotech Ltd (NASDAQ: SVA), Advaccine will evaluate the heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: INO shares are up 9.47% at $9.23 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.